UBX1325 is a groundbreaking Bcl-xL inhibitor in development for treating age-related eye diseases, including diabetic macular edema. It aims to selectively eliminate senescent cells in the eye's diseased vasculature, potentially transforming treatment paradigms for retinal diseases by preserving healthy vessels and restoring eye function.

Basic information

Country

USA

Group Name

Unity Biotechnology

Source

Source